Oligonucleotide-based molecular therapy for restenosis after angioplasty.
Molecular therapy is emerging as a potential strategy for the treatment of cardiovascular disease such as restenosis after angioplasty, vascular bypass graft occlusion, transplant coronary vasculopathy, homozygous familial hypercholesterolemia and cystic fibrosis, for which no known effective therapy exists. Molecular biology and pathophysiology of the cardiovascular system have started to emerge, and the time is ripe for the introduction of gene therapy to the management of cardiovascular disorders. In this review, we have focused on the future potential of oligonucleotide-based gene therapy for restenosis after angioplasty, which still remains an issue in the field of cardiovascular disease.
Aoki
Motokuni
M
Department of Geriatric Medicine, Osaka University Graduate School of Medicine, Suita, Japan. maoki@cgt.med.osaka-u.ac.jp
Morishita
Ryuichi
R
Ogihara
Toshio
T
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects* / Q000379:methods; D000818:Animals; D023903:Coronary Restenosis / Q000235:genetics* / Q000378:metabolism / Q000628:therapy*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage* / Q000235:genetics / Q000378:metabolism
D016376:Oligonucleotides, Antisense